Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer

(MedPage Today) -- CHICAGO--Combining standard transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen improved progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC), the phase...